ABSTRACT

The present investigation was undertaken to evaluate the effective dose for the induction of diabetes by alloxan in Wistar rats. Alloxan and streptozotocin (STZ) are the most widely used in diabetes studies, and alloxan is the most affordable. Alloxan is a glucose analogue-like structure; it enters the ? cell of the endocrine pancreas through the GLUT2 glucose transporter and destroys it by forming ROS (reactive oxygen species), and insulin hormone secretion is hampered. Alloxan causes a condition known as "Alloxan Diabetes," like human type 1 diabetes. But in some cases, due to the short half-life of alloxan, which will spontaneously decompose into alloxanic acid in an aqueous solution within minutes, alloxan is therefore non- diabetic and non-responsive. Few-induced animals are auto-reversed from diabetic to normal animals within a few days after the induction of alloxan due to the regeneration of ? cells. In some cases, alloxan is non-responsive and cannot induce diabetes because young animals are highly resistant to the toxic effects of alloxan. So, we needed to find out the best and most successful dose selection for the initiation of diabetes in the Wister rat under laboratory conditions. In our study, intraperitoneal administration of 150 mg of alloxan per kilogram of rat body weight produced the most adequate conditions for inducing diabetes mellitus in rats. The induction success rate was lower in the higher group (160–170 mg/kg b.w.) and had a higher mortality rate. Lower doses of alloxan (110–140 mg/kg b.w.) can result in fewer diabeticanimals, a high number of non-responsive animals, and a high rate of auto-reversion for diabetics to a normoglycemic state within seven days. Keywords: Diabetes, Alloxan, Streptozotocin, ROS, ? cell, intraperitoneal
Publication date: 01/10/2024

https://ijbpas.com/pdf/2024/October/MS_IJBPAS_2024_8401.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.10.8401